Genotyping services partners

Cytox has partnered with leading CLIA-compliant genomic laboratories running the Applied Biosystems GeneTitan Multi-Channel (MC) Instrument platform to offer Alzheimer’s disease risk assessment globally to pharma, biotech and research labs pursuing clinical research and drug development in Alzheimer’s disease.


AKESOgen is a biomarker, genomics and pharmacogenomics contract research organization performing biomarker profiling and genomics services utilizing different types of markers (e.g. DNA, RNA, methylation) for the R&D market. AKESOgen provides premier research services and the highest quality data with scientists with decades of genomics experience. Serving clients in biotech, pharmaceutical, academic and government research/testing, the company offers CLIA compliant lab with strict process controls.


Eurofins Genomics, a member of the Eurofins Group with facilities in Europe, the United States and Asia, is an internationally leading provider of DNA sequencing services, genotyping services, DNA synthesis products and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological and research markets. The company's strength is its extensive customer base and high quality services in industrial scale for the life science industries and academic research institutions around the world.

Cytox assays can be run with service laboratories equipped to run the Applied Biosystems GeneTitan Multi-Channel Instrument platform anywhere in the world as selected in partnership with the study sponsor. We have positive experience with such laboratories in Europe, USA and the UK.

Platform Partner

Cytox has developed the groundbreaking variaTECT™ SNP research array for assessing Alzheimer’s disease risk. The variaTECT panel utilises the proven power and scalability of the Applied Biosystems™ GeneTitan™ Multi-Channel (MC) Instrument platform from Thermo Fisher Scientific. The array is easy to administer and simply requires genomic DNA, e.g. from a blood or saliva sample, clinical sample archive or biobanked DNA. Cytox offers genomic profiling testing assays and services globally to pharmaceutical and biotechnology companies and research laboratories pursuing clinical research and drug development.

Working with Cytox

Cytox welcomes enquiries from all organisations interested in our groundbreaking approach to identify an individual’s genetic risk component for developing Alzheimer's disease:

  • Our commercial ready testing services are available today in North America and Europe as prognostic tests for identifying those at highest risk for cognitive decline and developing Alzheimer’s disease by organisations such as pharmaceutical and biotechnology companies, CROs and grant funded academic researchers. These entities are seeking more accurate and affordable prognostic approaches for identifying those at highest risk for cognitive decline and developing Alzheimer’s disease
  • Collaborators who want to learn more about how Cytox can license and commercialise their algorithms
  • Laboratory Services who want to offer our approach in Asia or Africa
  • Ecosystem partners who have synergistic technologies that could be taken to market together.

Please contact us via the contact form, on +44 (0) 1865 338 018 or at